Warner Chilcott Mum On Potential Suitors
This article was originally published in The Pink Sheet Daily
Warner Chilcott didn’t address the elephant in the room – a potential acquisition – during its first quarter earnings call.
You may also be interested in...
Warner Chilcott has ended all discussions with parties potentially interested in buying the company and tried to satisfy investors with a special dividend as a consolation prize.
As second quarter earnings announcement shift into high gear, companies announce changes to manufacturing, progress on their drug launch efforts and their intentions to ramp up business development efforts.
Success of petition seeking to block single-scored generics of Doryx will likely rest on the brand firm's ability to make a safety and efficacy case for its dual-scored version of the antibiotic, which may be difficult given that it was marketed as a single-scored tablet for so long.